Antifolate agents: a patent review (2006 – 2010)

Bibliography

• Bertino J. Karnofsky memorial lecture: Ode to methotrexate. J Clin Oncol 1993;21:5-14
   Google Scholar
• Liu J, Bolstad D, Smith A, Structure-guided development of efficacious antifungal agents targeting candida glabrata dihydrofolate reductase. Chem Biol 2008;15:990-96
   PubMedGoogle Scholar
• Liu J, Bolstad D, Smith A, Probing the active site of candida glabrata dihydrofolate reductase with high resolution crystal structures and the synthesis of new inhibitors. Chem Biol Drug Des 2009;73:62-74
   PubMedGoogle Scholar
• Cody V, Galitsky N, Rak D, Ligand-induced conformational changes in the crystal structures of Pneumocystis carinii dihydrofolate reductase complexes with folate and Nadp+. Biochemistry 1999;38:4303-12
   PubMed Web of Science ®Google Scholar
• Cody V, Pace J. Structural analysis of Pneumocystis carinii and human DHFR complexes with NADPH and a series of five potent 6-[5′-(w-carboxyalkoxy)benzyl]-pyrido[2,3-d]pyrimidine derivatives. Acta Cryst 2011;D67:1-7
   Google Scholar
• Cody V, Pace J, Chisum K, New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent trimethoprim derivatives. Proteins 2006;65:959-69
   PubMedGoogle Scholar
• Lee J, Yennawar N, Gam J, Kinetic and structural characterization of dihydrofolate reductase from Streptococcus pneumoniae. Biochemistry 2010;49:195-206
   Google Scholar
• Beierlein J, Frey K, Bolstad D, Synthetic and crystallographic studies of a new inhibitor series targeting bacillus anthracis dihydrofolate reductase. J Med Chem 2008;51:7532-40
   PubMed Web of Science ®Google Scholar
• Bennett B, Xu H, Simmerman R, Crystal structure of the anthrax drug target, bacillus anthracis dihydrofolate reductase. J Med Chem 2007;50:4374-81
   PubMed Web of Science ®Google Scholar
• Bourne C, Bunce R, Bourne P, Crystal strucutre of Bacillus anthracis dihydrofolate reductase, with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity. Antimicrob Agents and Chem 2009;53:3065-73
   PubMed Web of Science ®Google Scholar
• Beierlein J, Karri N, Anderson A. Targeted mutations of bacillus anthracis dihydrofolate reductase condense complex structure-activity relationships. J Med Chem 2010;53:7327-36
   Google Scholar
• Beierlein J, Deshmukh L, Frey K, The solution structure of bacillus anthracis dihydrofolate reductase yields insight into the analysis of structure-activity relationships for novel inhibitors. Biochemistry 2009;48:4100-8
   Google Scholar
• Heaslet H, Harris M, Fahnoe K, Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim. Proteins 2009;76:706-17
   PubMed Web of Science ®Google Scholar
• Hay S, Evans R, Levy C, Are the catalytic properties of enzymes from piezophilic organisms pressure adapted? Chem Bio Chem 2009;10:2348-53
   Google Scholar
• Frey K, Georgiev I, Donald B, Predicting resistance mutations using protein design algorithms. Proc Natl Acad Sci 2010;107:13707-12
   Google Scholar
• Frey K, Liu J, Lombardo M, Crystal structures of wild-type and mutant methicillin-resistant staphylococcus aureus dihydrofolate reductase reveal an alternative conformation of NADPH that may be linked to trimethoprim resistance. J Mol Biol 2009;387:1298-308
   Google Scholar
• Frey K, Lombardo M, Wright D, Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant staphylococcus aureus dihydrofolate reductase. J Struc Biol 2010;170:93-7
   Google Scholar
• Oefner C, Bandera M, Haldimann A, Increased hydrophobic interactions of iclaprim with staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J Antimicrob Chemother 2009;63:687-98
   PubMed Web of Science ®Google Scholar
• Oefner C, Parisi S, Schulz H, Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus. Acta Cryst 2009;D65:751-57
   Google Scholar
• Bourne C, Barrow E, Bunce R, Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1. Antimicrob Agents and Chem 2010;54:3825-33
   PubMed Web of Science ®Google Scholar
• Cody V, Piraino J, Pace J, Preferential selection of isomer binding from chiral mixtures: alternate binding modes observed for the E and Z isomers of a series of 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines as ternary complexes with NADPH and human dihydrofolate reductase. Acta Cryst 2010;D66:1271-77
   Google Scholar
• Gangjee A, Li W, Kisliuk R, Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents. J Med Chem 2009;52:4892-902
   PubMed Web of Science ®Google Scholar
• Reynolds R, Campbell S, Fairchild R, Novel boron-containing, nonclassical antifolates: synthesis and preliminary biological and structural evaluation. J Med Chem 2007;50:3283-89
   PubMedGoogle Scholar
• Costi M, Rinaldi M, Tondi D, Phthalein derivatives as a new tool for selectivity in thymidylate synthase inhibition. J Med Chem 1999;42:2112-24
   Google Scholar
• Stout T, Tondi D, Rinaldi M, structure-based design of inhibitors specific for bacterial thymidylate synthase. Biochemistry 1999;38:1607-17
   Google Scholar
• Schormann N, Senkovich O, Walker K, Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function. Proteins 2008;73:889-901
   PubMed Web of Science ®Google Scholar
• Schormann N, Velu S, Murugesan S, Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase. Bioorg Med Chem 2010;18:4056-66
   PubMed Web of Science ®Google Scholar
• Chitnumsub P, Yuvaniyama J, Chahomchuen T, Crystallization and preliminary crystallographic studies of dihydrofolate reductase-thymidylate synthase from Trypanosoma cruzi, the Chagas disease pathogen. Acta Cryst 2009;F65:1175-78
   Google Scholar
• Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 2003;10:357-65
   PubMedGoogle Scholar
• Dasgupta T, Chitnumsub P, Kamchonwongpaisan S, Exploiting structural analysis, in silico screening, and serendipity to identify novel inhibitors of drug-resistant falciparum malaria. ACS Chem Biol 2009;4:29-40
   PubMed Web of Science ®Google Scholar
• Nzila A, Rottman M, Chitnumsub P, Preclinical evaluation of the antifolate QN254, 5-chloro-N′6′-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate. Antimicrob Agents and Chem 2010;54:2603-10
   PubMed Web of Science ®Google Scholar
• Medicines for malaria venture. Antimalarial compounds with flexible side-chains. WO09048957; 2009
   Google Scholar
• Sirawaraporn W, Sathitkul T, Sirawaraporn R, Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci 1997;94:1124-9
   PubMed Web of Science ®Google Scholar
• University of Connecticut. Inhibitors of Dihydrofolate reductase with antibacterial, antiprotozoal, antifungal and anticancer properties. US20090105287; 2009
   Google Scholar
• Pelphrey P, Popov V, Joska T, Highly efficient ligands for DHFR from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis. J Med Chem 2007;50:940-50
   PubMed Web of Science ®Google Scholar
• Dana-Farber Cancer Institute. Pharmaceutically active compounds and methods of use thereof. 7119095; 2006
   Google Scholar
• Auspex Pharmaceuticals. Diaminoquinazoline inhibitors of dihydrofolate reductase. 20100150896; 2010
   Google Scholar
• Dihydrofolate reductase inhibition by epigallocatechin gallate compounds. US20070249545; 2007
   Google Scholar
• Chroma Therapeutics. Pyrimidine derivatives useful as DHFR inhibitors. WO07129020; 2007
   Google Scholar
• Chroma Therapeutics. DHFR enzyme inhibitors. WO07132146; 2007
   Google Scholar
• Dana-Farber Cancer Institute. Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same. US6989386; 2006
   Google Scholar
• Novel inhibitors of folic acid-dependent enzymes. US20100249141; 2010
   Google Scholar
• Inhibitors of folic acid-dependent enzymes. US7718660; 2010
   Google Scholar
• Chelsea Therapeutics. New classical antifolates. US20080214585; 2008
   Google Scholar
• Abraham A, McGuire J, Galivan J, Folate analogs. 34. Synthesis and antitumor activity of non-polyglutamylatable inhibitors of dihydrofolate reductase. J Med Chem 1991;34:222-7
   PubMedGoogle Scholar
• BTG International Ltd. Anti-cancer cyclopenta[g]quinazoline compounds. US7705006; 2010
   Google Scholar
• Duquesne University of the Holy Spirit. Thieno pyrimidine compounds. US20090326224; 2009
   Google Scholar